Commentary

Podcast

Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment

A brief overview of 4 recent developments in the treatment of non-small cell lung cancer.

This podcast episode provided an oncology news roundup focusing on 4 updates related to non-small cell lung cancer treatment. It discussed the role of pharmacists in chemotherapy management for NSCLC patients and barriers like insurance coverage. It also reviewed two recent FDA drug approvals for advanced NSCLC and results from a phase 3 trial that did not meet its primary endpoint.

Timestamps

[0:00:27-0:01:00] - Pharmacists' involvement among patients with non-small cell lung cancer
[0:01:00-0:02:00] - FDA approval of osimertinib in combination with chemotherapy for EGFR-mutated NSCLC
[0:02:00-0:02:30] - FDA approval of datopotamab deruxtecan for previously treated NSCLC
[0:02:30-0:03:17] - Phase 3 trial of sacituzumab govitecan in metastatic NSCLC that did not meet its primary endpoint

Key Takeaways

  1. Pharmacists play an important role in chemotherapy management for NSCLC patients, but insurance coverage can be a barrier.
  2. Osimertinib in combination with chemotherapy received FDA approval for locally advanced or metastatic EGFR-mutated NSCLC and showed improved progression-free survival.
  3. Datopotamab deruxtecan received FDA approval for previously treated locally advanced or metastatic non-squamous NSCLC.
  4. A phase 3 trial of sacituzumab govitecan failed to meet its primary endpoint of improved overall survival in metastatic NSCLC, though some benefit was seen in squamous and non-squamous subgroups.

Related Videos
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously
Related Content
Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma
December 20th 2024

Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma

George DeMaagd, PharmD, BCPS Gregory Franz, MD, MPH Zachery Halford, PharmD, BCOP, BCPPS
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Depiction of colorectal cancer tumor growth Image Credit: © Dr_Microbe - stock.adobe.com
December 18th 2024

Chronic Inflammation Driven by Diet May Contribute to Colorectal Cancer, Study Finds

Alexandra Gerlach, Associate Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Small Cell Lung Cancer Cells: These small, round cells in the lungs divide rapidly and are known for early metastasis, resulting in highly aggressive cancer.
December 17th 2024

Sacituzumab Govitecan-hziy Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Treatment

Luke Halpern, Assistant Editor
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com
December 16th 2024

FDA Approves Cosibelimab-Ipdl for Adult Patients with mCSCC or laCSCC

Gillian McGovern, Assistant Editor